Nine of 49 (18.4%) ECs with a predicted pathogenic POLE mutation (including four known hotspot mutations) were MSI‐H, compared with 26/33 (78.8%) tumours with a predicted non‐pathogenic mutation (p ≤ 0.0001, χ2 statistic). This evidence concerns the gene POLE and neoplasm.